Join
Live feed
·
PRReleasevia Quantisnow
Bolt Biotherapeutics Inc. logo

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021

ByQuantisnow·Wall Street's wire, on your screen.
BOLT· Bolt Biotherapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BOLT (Bolt Biotherapeutics Inc.) and more on Quantisnow.